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costs were also modeled using linear regression. In this
model the “Grier-effect” was estimated by using a dummy
variable. RESULTS: For all months (November 2000–
July 2001) projected PMPM cost of antibiotic therapy
was lower than actual PMPM cost of antibiotic therapy.
The r-squared for the model was 0.96. The 9-month
average for projected PMPM antibiotic costs was $2.52
and actual PMPM antibiotic costs were $3.51, for an
average differential of nearly $1.00. The extrapolated
cost differential over the forecasted 9-month period was
$12.5 million. This translates into $16.7 million in addi-
tional annual costs for antibiotic therapy due to the
“Grier-effect”. Regression analysis of the effects of Grier
indicated the GCD increased expenditures for antibiotics
by 30% (p < 0.0001). According to regression modeling,
a 30% increase in expenditures due to Grier increased
costs of antibiotic therapy by $18.3 million. CONCLU-
SIONS: The GDC signiﬁcantly increased antibiotic
expenditures, resulting in an additional ~$17–18 million
in annual costs. Additional research is necessary to assess
whether this increase improved quality.
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OBJECTIVE: Community Acquired Pneumonia (CAP) is
a major cause of mortality and healthcare resource use
worldwide. Proper management of less severe outpatient
CAP has demonstrated resource savings without adverse
patient outcomes. Although treatment guidelines recom-
mend the use of certain pharmacological agents such as
macrolides, ﬂuoroquinolines or doxycycline for outpa-
tient CAP, limited data are available on actual usage. We
aim to describe current antibiotic prescribing patterns
using a large prescription database. METHODS: The
study population comprised IMS MediPlus-UK. Adult
CAP outpatients (ICD-10: J13–J15) diagnosed during
January 1, 1997 through December 31, 2001 and treated
with antibiotics were included. Patients were followed
through the initial duration of therapy and an additional
4-week period to capture the original therapy and 
added antibiotic use. Those with HIV/AIDS were
excluded. Antibiotics were categorized as “penicillins”,
“cephalosporins”, “macrolides”, “tetracyclines”, “quino-
lones”, and “other” (including multisubstance and
trimethoprim). RESULTS: Among 739 episodes identi-
ﬁed, most were initially treated by penicillin group
(including amoxicillin, ampicillin, penicillin, 41%), and
macrolides (erythromycin, azithromycin, clarithromyc,
28%). Cephalosporins, tetracyclines, and quinolones
were used less often, 10%, 4% and 5%, respectively. The
median prescribed length of therapy was 7 days, except
tetracyclines (6). The means (days)(standard deviation)
were: 6.9(2.8)for penicillins, 7.4(1.9)for cephalosporins,
9.5(17.2) for macrolides, 6.3(2.5) for tetracyclines,
6.4(1.5) for quinolones, and 6.7(1.5) for other. The per-
centage of patients received a second antibiotic during
study period ranged from 15% to 23%, with the second
round mostly in the same category as the initial antibi-
otic. CONCLUSIONS: Duration of therapy for CAP out-
patients remains relatively long in this UK population. 
A substantial proportion of patients received additional
therapy during the episode of care. Long therapy dura-
tion has been associated with patient nonadherence,
and/or treatment failure. Effective therapy options with
shorter length of therapy are needed to improve CAP out-
patient management and patient outcomes.
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OBJECTIVE: In February 2001, the Ontario Drug Beneﬁt
(ODB) Formulary was changed so that most ﬂuoro-
quinolone (FQ) antibiotics would be subject to Limited
Use (LU) restrictions. Only norﬂoxacin remained as
General Beneﬁt (GB). This study analyzed the impact 
of the LU policy on ODB antibiotic volume and expen-
ditures. METHODS: We analysed monthly ODB data on
prescribing volumes and expenditures of 29 types of
antibiotics over the period (January 1999 to November
2001). Ordinary least squares (OLS) regression with a
robust estimator of the standard errors was used to esti-
mate the effect of LU on the pre-policy trend in antibi-
otic use and expenditures. Estimates from these models
were used to predict the cumulative impact of LU on out-
comes in the 10 month post-LU policy period (February
to November 2001). RESULTS: Of the 29 types of antibi-
otics included in this analysis (with total ODB prescrip-
tions and expenditures of 2.3 million and CDN$55
million in 2000), changes for ciproﬂoxacin and nor-
ﬂoxacin were the greatest in magnitude. We observed a
shift in prescriptions and expenditures from LU FQs 
(-167,764, p < 0.00; -$8,963,635, p < 0.00, respectively)
to GB FQs (45,126, p < 0.00; $2,069,956, p < 0.00).
However, while FQ prescriptions and expenditures
decreased signiﬁcantly (-118,020, p < 0.00; -$6,662,708,
p < 0.00), we found no signiﬁcant change in either total
number of antibiotics prescribed or total antibiotic expen-
ditures after LU. Also, prescriptions for trimethoprim sul-
famethoxazole (TMP/SMX) increased signiﬁcantly.
CONCLUSIONS: Although no direct cause and effect
can be shown with these observational data, the results
suggest that the change in reimbursement policy to
restrict prescribing of FQs did not signiﬁcantly affect
overall ODB antibiotic prescriptions and expenditures.
Although use of and expenditures on restricted FQs were
reduced signiﬁcantly, there was an offsetting increase in
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the use of other antibiotics. We conducted a subsequent
study to determine the impact of the policy on resistance
rates.
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OBJECTIVE: It has been asserted that “decisions regard-
ing the allocation of public HIV prevention funds repre-
sent the single most important set of HIV prevention
decisions made,” (Ruiz et al., 2000; p.19). As a result,
several approaches to allocating these funds have been
proposed. However, the application of these models is
limited because the measurements of performance are
usually not quantiﬁable in real practice. This research
outlines a resource allocation model that can be used 
to assist decision-makers in allocating HIV prevention
funds. METHODS: The current process of allocating
HIV prevention funds within various states was reviewed
in detail. Speciﬁcally, population subgroup, intervention,
and geographical issues were considered. In addition,
measures of successful intervention implementation were
identiﬁed. After this thorough review, parameters (i.e.,
prevalence, infectivity, input from local planning groups)
deemed to be important in determining the proper allo-
cation of funds were identiﬁed. These parameter choices
were guided by the need to be able to estimate parame-
ter values from available data systems. Using linear pro-
gramming techniques, a model based on our parameter
choices was developed for used by decision-makers that
incorporates a quantiﬁable measure of success. This
model also includes funding and equity constraints.
RESULTS: An allocation of funds can be made such that
several system constraints can be considered and the
model can be validated through prospective data collec-
tion. The model was programmed in Microsoft Excel®
with a user-friendly interface and was prototyped within
a state health department’s allocation system.
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OBJECTIVES: Current guidelines recommend pravas-
tatin or atorvastatin, and not lovastatin or simvastatin,
to avoid drug interactions in PI-treated HIV+ patients
requiring dyslipidemia treatment. Because limited data
are currently available on the historical management 
of dyslipidemia within the PI-treated HIV+ population,
we examined the annual utilization trend of non-
recommended HMG-CoA reductase inhibitors (statins)
within this population. METHODS: This was a retro-
spective, cross-sectional analysis using pharmacy claims
from 1998–2001 from a managed care organization
(MCO) of about 3.5 million lives. Patients with at least
2 claims for antiretroviral therapy with a cumulative
days’ supply >30 and concurrent statin-PI utilization
during the same calendar year were included. Logistic
regression was used to evaluate whether age, gender, 
or physician specialty were associated with non-
recommended statin use. RESULTS: There were 4 non-
mutually exclusive yearly cohorts with 492 unique HIV+
patients with concurrent statin-PI therapy (1998 :n = 141;
1999 :n = 224; 2000 :n = 231; 2001 :n = 250). Mean ages
ranged from 45.7–47.3 years and >95% were male. There
were 58 occurrences (6.9%) of concurrent simvastatin-PI
utilization between 1998–2001. No concurrent lovas-
tatin-PI was identiﬁed. Most patients (72.5%) received
their statins and PI from the same physician. Patients
receiving these medications from different physicians
were signiﬁcantly more likely to have concurrent simvas-
tatin-PI utilization (OR: 2.01, 95% CI: 1.13–3.58).
Although no overall trend in simvastatin-PI utilization
was observed, a signiﬁcant decreasing trend was seen
among infectious disease (ID) physicians (p = 0.04).
CONCLUSIONS: As this patient population and its
longevity grow, the quality of their management becomes
increasingly important. Since simvastatin and lovastatin
were not on this MCO’s formulary, the prevalence of non-
recommended statin use was low. Nevertheless, we found
a proportion of patients who received concurrent sim-
vastatin-PI and a decreasing utilization trend among ID
physicians as guidelines became better established.
Awareness, however, among non-ID physicians may still
need to be improved and greater coordination established
between different physician prescribers of statin and PI
therapy.
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OBJECTIVES: To assess potential implications of 
applying four competing national guidelines addressing
antibiotic prophylaxis of Total Hip Replacement (THR)
surgery. METHODS: Four guidelines were applied to a
random sample of 386 medical records of patients who
underwent THR surgery from January 1999 to Decem-
ber 2000. Setting: Orthopaedic surgery wards in a 2200-
bed French teaching hospital. Main outcome measure:
Compliance of physician practice with the French guide-
line (French National Agency of Accreditation and Health
